See more : Aeris Environmental Ltd (AEI.AX) Income Statement Analysis – Financial Results
Complete financial analysis of DURECT Corporation (DRRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DURECT Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- The Container Store Group, Inc. (TCS) Income Statement Analysis – Financial Results
- Scienjoy Holding Corporation (SJOYW) Income Statement Analysis – Financial Results
- Sustainable Opportunities Acquisition Corp. (SOAC) Income Statement Analysis – Financial Results
- Agnico Eagle Mines Limited (AEM.TO) Income Statement Analysis – Financial Results
- Kincora Copper Limited (KCC.AX) Income Statement Analysis – Financial Results
DURECT Corporation (DRRX)
About DURECT Corporation
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.55M | 19.28M | 13.98M | 30.11M | 29.56M | 18.56M | 49.17M | 14.03M | 19.12M | 19.40M | 15.33M | 53.07M | 33.49M | 31.59M | 24.29M | 25.96M | 30.68M | 21.89M | 28.57M | 13.85M | 11.84M | 7.19M | 6.52M | 3.16M | 86.00K |
| Cost of Revenue | 1.72M | 1.59M | 1.96M | 1.41M | 4.14M | 4.26M | 6.63M | 5.29M | 3.91M | 5.69M | 4.84M | 4.65M | 4.71M | 4.28M | 5.34M | 3.37M | 3.23M | 3.25M | 2.82M | 2.73M | 2.43M | 3.09M | 3.40M | 1.29M | -272.00K |
| Gross Profit | 6.83M | 17.70M | 12.02M | 28.71M | 25.42M | 14.30M | 42.54M | 8.74M | 15.22M | 13.72M | 10.49M | 48.42M | 28.77M | 27.32M | 18.95M | 22.59M | 27.45M | 18.65M | 25.76M | 11.12M | 9.41M | 4.10M | 3.13M | 1.86M | 358.00K |
| Gross Profit Ratio | 79.91% | 91.76% | 86.01% | 95.33% | 85.99% | 77.04% | 86.51% | 62.28% | 79.58% | 70.69% | 68.44% | 91.23% | 85.93% | 86.47% | 78.01% | 87.04% | 89.49% | 85.16% | 90.15% | 80.30% | 79.49% | 57.05% | 47.92% | 59.08% | 416.28% |
| Research & Development | 29.35M | 36.86M | 31.85M | 27.71M | 30.21M | 25.50M | 31.61M | 29.27M | 24.32M | 22.43M | 18.95M | 20.27M | 34.05M | 36.21M | 34.91M | 39.41M | 38.34M | 37.24M | 28.90M | 24.23M | 20.95M | 29.55M | 24.57M | 13.34M | 6.36M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.42M | 13.17M | 11.83M | 11.57M | 12.28M | 12.71M | 12.10M | 13.57M | 14.94M | 15.02M | 15.46M | 13.62M | 12.42M | 11.27M | 9.95M | 8.40M | 12.17M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 116.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.36M | 15.92M | 14.45M | 13.61M | 14.36M | 12.42M | 13.17M | 11.83M | 11.57M | 12.28M | 12.71M | 12.10M | 13.57M | 14.94M | 15.14M | 15.46M | 13.62M | 12.42M | 11.27M | 9.95M | 8.40M | 12.17M | 12.08M | 9.85M | 3.04M |
| Other Expenses | 0.00 | 23.66M | 25.52M | 3.77M | 12.08M | 17.29M | 8.03M | 27.39M | 16.49M | 14.17M | 15.36M | 0.00 | 11.69M | 16.12M | 22.45M | 48.00K | 31.00K | 424.00K | 1.21M | 1.25M | 1.34M | 1.34M | 1.84M | 1.50M | 311.00K |
| Operating Expenses | 43.72M | 52.78M | 46.30M | 41.32M | 44.57M | 37.92M | 44.77M | 41.10M | 35.88M | 34.71M | 31.65M | 32.36M | 47.63M | 51.15M | 50.05M | 68.40M | 51.99M | 50.08M | 41.38M | 35.43M | 30.69M | 43.07M | 38.50M | 24.69M | 9.72M |
| Cost & Expenses | 45.43M | 54.37M | 48.25M | 42.73M | 48.72M | 42.18M | 51.41M | 46.39M | 39.79M | 40.40M | 36.49M | 37.01M | 52.34M | 55.43M | 55.39M | 71.77M | 55.22M | 53.33M | 44.20M | 38.16M | 33.11M | 46.15M | 41.90M | 25.98M | 9.45M |
| Interest Income | 2.13M | 2.15M | 156.00K | 517.00K | 1.07M | 870.00K | 967.00K | 143.00K | 237.00K | 39.00K | 0.00 | 151.00K | 134.00K | 943.00K | 420.00K | 1.55M | 0.00 | 3.83M | 2.27M | 0.00 | 1.04M | 0.00 | 0.00 | 3.10M | 0.00 |
| Interest Expense | 2.79M | 2.40M | 2.15M | 2.24M | 2.50M | 2.57M | 2.43M | 2.29M | 2.24M | 1.15M | 290.00K | 7.00K | 46.00K | 6.00K | 36.00K | 789.00K | 2.63M | 3.44M | 4.36M | 0.00 | 2.46M | 0.00 | 0.00 | 131.00K | 0.00 |
| Depreciation & Amortization | 148.00K | 150.00K | 132.00K | 297.00K | 291.00K | 254.00K | 437.00K | 416.00K | 425.00K | 601.00K | 558.00K | 964.00K | 1.18M | 2.25M | 2.51M | 48.00K | 2.32M | 2.46M | 3.17M | 4.64M | 4.75M | 4.32M | 3.30M | 1.50M | 311.00K |
| EBITDA | -24.68M | -32.78M | -33.99M | -11.80M | -18.58M | -22.50M | -833.00K | -31.81M | -20.00M | -20.36M | -20.60M | 17.16M | -17.59M | -20.64M | -27.75M | -45.76M | -22.22M | -28.97M | -12.46M | -18.43M | -16.53M | -34.65M | -32.07M | -21.32M | -9.05M |
| EBITDA Ratio | -288.77% | -170.79% | -244.09% | -40.18% | -61.15% | -122.54% | -2.58% | -229.74% | -106.81% | -108.03% | -138.08% | 32.36% | -56.30% | -75.45% | -129.75% | -176.30% | -70.11% | -121.89% | -42.20% | -141.98% | -139.70% | -482.25% | -276.58% | -675.85% | -10,520.93% |
| Operating Income | -36.88M | -35.08M | -34.27M | -12.62M | -19.15M | -23.62M | -2.24M | -32.36M | -20.66M | -21.00M | -21.16M | 16.06M | -18.85M | -23.84M | -31.10M | -45.81M | -24.54M | -31.44M | -15.63M | -24.31M | -21.28M | -38.97M | -49.40M | -22.82M | -9.36M |
| Operating Income Ratio | -431.49% | -181.93% | -245.21% | -41.89% | -64.78% | -127.23% | -4.55% | -230.76% | -108.05% | -108.23% | -138.08% | 30.25% | -56.30% | -75.45% | -128.02% | -176.48% | -80.00% | -143.58% | -54.70% | -175.48% | -179.80% | -542.37% | -757.23% | -723.39% | -10,882.56% |
| Total Other Income/Expenses | 9.26M | -251.00K | -1.99M | -1.72M | -1.43M | -1.70M | -1.46M | -2.15M | -2.00M | -1.11M | -290.00K | 144.00K | 88.00K | 937.00K | 811.00K | 758.00K | 202.00K | -1.89M | -2.50M | -3.31M | -1.42M | 1.80M | 4.47M | 0.00 | 0.00 |
| Income Before Tax | -27.62M | -35.33M | -36.27M | -14.34M | -20.58M | -25.32M | -3.70M | -34.51M | -22.66M | -22.11M | -21.45M | 16.20M | -18.77M | -22.90M | -30.29M | -43.91M | -24.34M | -33.33M | -18.12M | -27.62M | -22.70M | -37.17M | -44.93M | 0.00 | 0.00 |
| Income Before Tax Ratio | -323.16% | -183.23% | -259.46% | -47.61% | -69.60% | -136.40% | -7.51% | -246.05% | -118.51% | -113.96% | -139.97% | 30.53% | -56.04% | -72.48% | -124.68% | -169.15% | -79.34% | -152.22% | -63.43% | -199.37% | -191.79% | -517.37% | -688.66% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 251.00K | 1.86M | -11.81M | 2.21M | 870.00K | 530.00K | -273.00K | -188.00K | -562.00K | -558.00K | 151.00K | -1.18M | -2.25M | -2.89M | -12.69M | -202.00K | 1.89M | 4.00K | 18.00K | 0.00 | 0.00 | 9.56M | -2.97M | -651.00K |
| Net Income | -27.62M | -35.58M | -38.13M | -2.52M | -22.79M | -25.32M | -3.70M | -34.51M | -22.66M | -22.11M | -21.45M | 16.20M | -18.77M | -22.90M | -30.72M | -45.05M | -24.34M | -33.33M | -18.13M | -27.64M | -22.70M | -37.17M | -44.93M | -19.85M | -8.71M |
| Net Income Ratio | -323.16% | -184.54% | -272.77% | -8.38% | -77.08% | -136.40% | -7.51% | -246.05% | -118.51% | -113.96% | -139.97% | 30.53% | -56.04% | -72.48% | -126.44% | -173.56% | -79.34% | -152.22% | -63.45% | -199.50% | -191.79% | -517.37% | -688.66% | -629.19% | -10,125.58% |
| EPS | -1.22 | -1.56 | -1.69 | -0.13 | -1.28 | -1.60 | -0.25 | -2.60 | -1.91 | -2.00 | -2.10 | 1.80 | -2.15 | -2.64 | -3.68 | -5.75 | -3.45 | -5.05 | -3.37 | -5.37 | -4.49 | -7.69 | -9.68 | -11.60 | -3.66 |
| EPS Diluted | -1.20 | -1.56 | -1.69 | -0.13 | -1.28 | -1.58 | -0.25 | -2.59 | -1.91 | -1.98 | -2.08 | 1.80 | -2.15 | -2.64 | -3.68 | -5.75 | -3.45 | -5.05 | -3.37 | -5.37 | -4.49 | -7.69 | -9.68 | -6.01 | -3.66 |
| Weighted Avg Shares Out | 26.26M | 22.78M | 22.50M | 19.95M | 17.80M | 15.84M | 14.53M | 13.27M | 11.85M | 11.06M | 10.22M | 8.84M | 8.74M | 8.69M | 8.34M | 7.83M | 7.05M | 6.60M | 5.37M | 5.15M | 5.05M | 4.83M | 4.64M | 1.71M | 2.38M |
| Weighted Avg Shares Out (Dil) | 26.52M | 22.78M | 22.50M | 19.95M | 17.80M | 15.98M | 14.53M | 13.32M | 11.85M | 11.17M | 10.31M | 8.86M | 8.74M | 8.69M | 8.34M | 7.83M | 7.05M | 6.60M | 5.37M | 5.15M | 5.05M | 4.83M | 4.64M | 3.31M | 2.38M |
3 Promising Biotech Stocks That Will Make Early Investors Rich
For investment ideas that can potentially lead to life-changing gains, few sectors are as viable as biotech stocks to make you rich. Fundamentally, the biotechnology sector offers potential therapeutic innovations that could change paradigms for patient care.
DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis
Company on track to report topline data from AHFIRM in Q4 2023 CUPERTINO, Calif. , Sept. 7, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and...
DURECT Corporation Announces Presentations in Upcoming Investor Conferences
CUPERTINO, Calif. , Aug. 31, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic...
DURECT Corporation (DRRX) Q2 2023 Earnings Call Transcript
DURECT Corporation (NASDAQ:DRRX ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Timothy Papp - CFO & Secretary James Brown - Co-Founder, CEO, President & Director WeiQi Lin - EVP, Research & Development and Principal...
Durect (DRRX) Reports Q2 Loss, Misses Revenue Estimates
Durect (DRRX) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.50 per share a year ago.
DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update
CUPERTINO, Calif. , Aug. 3, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator...
DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
CUPERTINO, Calif. , July 20, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic liver diseases, today announced that it has entered...
DURECT Corporation (DRRX) Q1 2023 Earnings Call Transcript
DURECT Corporation (NASDAQ:DRRX ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Chief Executive Officer Keith Lui - Senior Vice President, Business Development, Commercial, Medical Affairs...
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates
Durect (DRRX) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.50 per share a year ago.
DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8
CUPERTINO, Calif. , May 1, 2023 /PRNewswire/ --- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2023 financial results and host a conference call after the market close on Monday, May 8, 2023.
Source: https://incomestatements.info
Category: Stock Reports